A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
about
Micafungin: an evidence-based review of its place in therapyComparison of echinocandin antifungalsAccumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.Micafungin: a sulfated echinocandin.Echinocandins: the newest class of antifungals.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Clinical hepatotoxicity associated with antifungal agents.Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infectionMicafungin in the treatment of invasive candidiasis and invasive aspergillosisA phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasisEfficacy and safety of echinocandins versus triazoles for the prophylaxis and treatment of fungal infections: a meta-analysis of RCTsPharmacokinetics of micafungin in subjects with severe hepatic dysfunction.New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.Developments in the treatment of candidiasis: more choices and new challenges.Micafungin: a new echinocandin antifungal.The echinocandins.The echinocandin micafungin: a review of the pharmacology, spectrum of activity, clinical efficacy and safety.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.Micafungin activity against Candida albicans with diverse azole resistance phenotypes.Micafungin sodium, the second of the echinocandin class of antifungals: theory and practice.A comparative evaluation of properties and clinical efficacy of the echinocandins.Clinical pharmacology of antifungal agents in pediatric patients.Micafungin for the prophylaxis and treatment of Candida infections.Current options in antifungal pharmacotherapy.Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066)Management of fungal infections following allogeneic stem cell transplantation.Pharmacoeconomic Analysis of Micafungin (Mycamine) 100 mg and 150 mg Daily In the Treatment of CandidemiaReview of the pharmacology and clinical studies of micafunginAntifungals to treat Candida albicans.Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.Invasive candidiasis: update on current pharmacotherapy options and future perspectives.Role of Echinocandins in Fungal Biofilm-Related Disease: Vascular Catheter-Related Infections, Immunomodulation, and Mucosal Surfaces.Echinocandins in antifungal pharmacotherapy.Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders.Short-term risk of liver and renal injury in hospitalized patients using micafungin: a multicentre cohort study.Echinocandins: A ray of hope in antifungal drug therapyDifferent doses of micafungin for prophylaxis of invasive fungal diseases in hemato-oncological high-risk patients: a web-based non-interventional trial in four large university hospitals in Germany.Clinical pharmacodynamic index identification for micafungin in esophageal candidiasis: dosing strategy optimization.Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders.EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole.
P2860
Q27014780-F8A9FD66-8731-421C-A05B-7F1E6A355BA6Q28273738-068C05F7-EE6C-421E-892A-EA6400A69BABQ33816237-6A442301-D08C-4302-82C4-D854A026DB05Q34015567-FC7E1D31-C3EB-4730-99B9-DB07637D93AEQ34019188-DCE4963E-EAE4-4D4E-9FAE-6D01BE66D53BQ34505582-DF6E1BDA-E44E-4E14-826F-65091DBFAFEDQ34546811-7A2C3BDA-1070-4A7B-9A31-B913B67AB21BQ34633796-C2F30CF8-53FE-4BE7-8E00-C0A9C3A73FCFQ35026516-8FB3012E-B944-412A-8C28-C3711059E811Q35076974-BCB0F1A3-518F-4885-ABB9-E7120295C511Q35515892-9BB404F7-68A2-4EE7-8A77-10891A718FA8Q36004967-B30F0686-3750-405F-A883-EA792DD6F6C2Q36597431-C4EA0FC3-6124-4FFF-B703-3E96C86552CDQ36623050-B06D9617-B041-40D7-81E6-DD9260185622Q36693843-64E5ECA9-4B58-4F44-8729-D8461729B29FQ36742397-038C6FA7-D66D-4A76-90ED-52C7DEBCA5CDQ36828156-B7B5B84A-AC79-4D41-8386-0DF761CC9321Q36845482-3043C62F-E4DC-43A7-9D81-5F811F6C3924Q36867925-3DB32FCE-2702-4FC0-85A0-5A762DF02CE8Q36895679-ABF67D86-6CA0-4D99-B296-9D79B5EE8153Q36895839-7BB84834-0BCF-46DB-9866-BD1653C52ACBQ36968140-DB1CE048-1239-495E-BC15-476AA3214338Q37124868-63CCC6D7-EA63-421B-A2F0-36BE12AE4FD1Q37151326-D561A164-B0D0-4FFE-BAE9-C18AAF5045E6Q37180338-E50416CF-1D5B-4ED5-9CF3-A77D49752B1FQ37202860-970AAC40-1043-4E38-A6D4-5715E6FD55D4Q37229198-F8D5A03F-B842-44DC-8B85-A57F72A8C1A2Q37669740-9E115A11-3550-45DB-AA18-F290708AE848Q37763928-8F88EE00-892A-4CC4-A382-30F663F9B06BQ38053482-0FC40D81-E748-48B9-88EC-00A13512DEBFQ38110850-FC06F18C-4AEA-4707-9CDB-BDF62325E64AQ38633105-2D75B4C4-680B-417A-848E-7ABAFEB3352AQ39458862-5163D313-B43A-44C1-A156-1B6B2FC6A3A3Q40313049-06B6363C-9342-45E8-BA81-2B44C37984D2Q40615864-9415DC09-F823-469A-87D9-EEF00B1C555FQ41066834-638FE7E1-DA53-4E4D-8A16-956814995BC0Q41676735-A0081F09-9E5C-440C-BA58-5389C2081AC4Q41929256-D58CA038-4692-4F8E-994F-04EFBB3F29B6Q43468516-D1007608-2F50-494D-AE50-53C0461BC9A9Q44013179-7E21517C-6C09-489F-83CD-AD43DE2AE41A
P2860
A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A randomized, double blind, co ...... nt of oesophageal candidiasis.
@en
A randomized, double blind, co ...... nt of oesophageal candidiasis.
@nl
type
label
A randomized, double blind, co ...... nt of oesophageal candidiasis.
@en
A randomized, double blind, co ...... nt of oesophageal candidiasis.
@nl
prefLabel
A randomized, double blind, co ...... nt of oesophageal candidiasis.
@en
A randomized, double blind, co ...... nt of oesophageal candidiasis.
@nl
P2093
P2860
P1476
A randomized, double blind, co ...... ent of oesophageal candidiasis
@en
P2093
Suleiman JM
Viljoen JJ
P2860
P304
P356
10.1111/J.1365-2036.2005.02427.X
P407
P577
2005-04-01T00:00:00Z